“Correction to Study on Personalized Therapy for Acute Lymphoblastic Leukemia with IKZF1 Deletion”

https://pubmed.ncbi.nlm.nih.gov/38113425

The abstract is about an erratum, or correction, to a study that found improved outcomes for acute lymphoblastic leukemia (ALL) in patients with IKZF1 deletion by prolonging therapy and decreasing therapy for other risk groups.